A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.

MLA

Scagliotti, Giorgio, et al. “A Phase 2 Randomized Study of TAS-102 versus Topotecan or Amrubicin in Patients Requiring Second-Line Chemotherapy for Small Cell Lung Cancer Refractory or Sensitive to Frontline Platinum-Based Chemotherapy.” Lung Cancer (Amsterdam, Netherlands), vol. 100, Oct. 2016, pp. 20–23. EBSCOhost, https://doi.org/10.1016/j.lungcan.2016.06.023.

APA

Scagliotti, G., Nishio, M., Satouchi, M., Valmadre, G., Niho, S., Galetta, D., Cortinovis, D., Benedetti, F., Yoshihara, E., Makris, L., Inoue, A., & Kubota, K. (2016). A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung Cancer (Amsterdam, Netherlands), 100, 20–23. https://doi.org/10.1016/j.lungcan.2016.06.023

Chicago

Scagliotti, Giorgio, Makoto Nishio, Miyako Satouchi, Giuseppe Valmadre, Seiji Niho, Domenico Galetta, Diego Cortinovis, et al. 2016. “A Phase 2 Randomized Study of TAS-102 versus Topotecan or Amrubicin in Patients Requiring Second-Line Chemotherapy for Small Cell Lung Cancer Refractory or Sensitive to Frontline Platinum-Based Chemotherapy.” Lung Cancer (Amsterdam, Netherlands) 100 (October): 20–23. doi:10.1016/j.lungcan.2016.06.023.